Weekly Analysts’ Ratings Updates for Immunic (IMUX)

Several brokerages have updated their recommendations and price targets on shares of Immunic (NASDAQ: IMUX) in the last few weeks:

• 4/15/2025 – Immunic had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 4/10/2025 – Immunic had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
• 4/1/2025 – Immunic had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
• 3/25/2025 – Immunic is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
• 3/20/2025 – Immunic was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 3/12/2025 – Immunic was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 2/26/2025 – Immunic had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
• 2/22/2025 – Immunic was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 2/21/2025 – Immunic had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 2/20/2025 – Immunic had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.

Immunic Stock Up 6.6 %

Immunic stock traded up $0.06 during mid-day trading on Tuesday, hitting $0.98. The company’s stock had a trading volume of 35,235 shares, compared to its average volume of 620,885. The stock has a market capitalization of $88.26 million, a P/E ratio of -0.80 and a beta of 1.91. The stock’s fifty day moving average price is $1.08 and its two-hundred day moving average price is $1.15. Immunic, Inc. has a twelve month low of $0.83 and a twelve month high of $2.11.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMUX. Invesco Ltd. bought a new stake in shares of Immunic during the 4th quarter worth about $37,000. Virtu Financial LLC bought a new stake in Immunic during the third quarter worth approximately $50,000. HB Wealth Management LLC bought a new position in shares of Immunic in the fourth quarter valued at approximately $81,000. Barclays PLC bought a new stake in shares of Immunic during the 4th quarter worth $84,000. Finally, Jane Street Group LLC increased its stake in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.